Association between management of metabolic syndrome and progression of early-stage chronic kidney disease: an observational cohort study

被引:7
作者
Lin, Jui-Hsiang [1 ,2 ,3 ]
Wu, Hung-Chieh [1 ,4 ]
Huang, Wen-Hung [2 ,3 ,5 ]
Lu, Chien-Lu [1 ,2 ,3 ]
Cheng, Mei-Hua [6 ]
Wang, Han-Ting [1 ]
Yen, Tzung-Hai [2 ,3 ,5 ]
Wang, Wei-Jie [1 ,4 ,7 ]
机构
[1] Tao Yuan Gen Hosp, Minist Hlth & Welf, Dept Internal Med, Div Nephrol, Taoyuan, Taiwan
[2] Chang Gung Mem Hosp, Dept Nephrol, Taipei 10591, Taiwan
[3] Chang Gung Mem Hosp, Div Toxicol, Taipei 10591, Taiwan
[4] Chang Gung Univ Sci & Technol, Coll Nursing, Taoyuan, Taiwan
[5] Chang Gung Univ, Coll Med, Taoyuan, Taiwan
[6] Tao Yuan Gen Hosp, Minist Hlth & Welf, Dept Rehabil, Taoyuan, Taiwan
[7] Chung Yuan Christian Univ, Dept Biomed Engn, Taoyuan, Taiwan
关键词
Chronic kidney disease; dyslipidemia; metabolic syndrome; renal function deterioration; RENAL-FUNCTION; RISK; ADULTS; TIME; HYPERTENSION; CHOLESTEROL; PREVALENCE; MORTALITY; DECLINE; MEN;
D O I
10.3109/0886022X.2014.964140
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To analyze the effect of treating metabolic syndrome (MetS) on further kidney function decline in patients with early-stage chronic kidney disease (CKD). Methods: In a study period of 24 months, 162 patients with early stage CKD were enrolled. Baseline and follow-up data related to the occurrence of MetS and glomerular filtration rate (GFR) were assessed. Subjects were classified into controlled MetS (group 1) and uncontrolled MetS (group 2). Furthermore, they were subdivided into four subgroups: (A) controlled MetS at baseline and at follow-up, (B) uncontrolled MetS at baseline but controlled MetS at follow-up visits, (C) controlled MetS at baseline but uncontrolled MetS at follow-up visits, and (D) uncontrolled MetS at baseline and follow-up visits. Results: Final GFR was lower in group 2 versus group 1 (69.21 +/- 20.20 vs. 82.86 +/- 22.33 mL/min/1.73 m(2), p < 0.001). The presence of MetS had high risk to develop late-stage CKD (HR = 3.279, 95% CI: 1.545-6.958, p = 0.002). Moreover, subgroup D (HR = 2.982, 95% CI: 1.287-6.908, p = 0.011) and the presence of three (p = 0.026) or four (p = 0.049) metabolic components had high risk to develop late-stage CKD. Conclusion: Treating MetS slows CKD progression in patients with early-stage of CKD.
引用
收藏
页码:29 / 36
页数:8
相关论文
共 29 条
[1]   Kidney Pathological Changes in Metabolic Syndrome: A Cross-sectional Study [J].
Alexander, Mariam P. ;
Patel, Tejas V. ;
Farag, Youssef M. K. ;
Florez, Adriana ;
Rennke, Helmut G. ;
Singh, Ajay K. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (05) :751-759
[2]   Preserving renal function in adults with hypertension and diabetes: A consensus approach [J].
Bakris, GL ;
Williams, M ;
Dworkin, L ;
Elliott, WJ ;
Epstein, M ;
Toto, R ;
Tuttle, K ;
Douglas, J ;
Hsueh, W ;
Sowers, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 36 (03) :646-661
[3]  
Barylski M, 2011, ARCH MED SCI, V7, P1055, DOI [10.5114/AOMS.2011.26620, 10.5114/aoms.2011.26620]
[4]   Staging of chronic kidney disease: Time for a course correction [J].
Bauer, Carolyn ;
Melamed, Michal L. ;
Hostetter, Thomas H. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 19 (05) :844-846
[5]   Metabolic Syndrome and Insulin Resistance as Risk Factors for Development of Chronic Kidney Disease and Rapid Decline in Renal Function in Elderly [J].
Cheng, Hui-Teng ;
Huang, Jenq-Wen ;
Chiang, Chih-Kang ;
Yen, Chung-Jen ;
Hung, Kuan-Yu ;
Wu, Kwan-Dun .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (04) :1268-1276
[6]   Dipstick Proteinuria as a Screening Strategy to Identify Rapid Renal Decline [J].
Clark, William F. ;
Macnab, Jennifer J. ;
Sontrop, Jessica M. ;
Jain, Arsh K. ;
Moist, Louise ;
Salvadori, Marina ;
Suri, Rita ;
Garg, Amit X. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 22 (09) :1729-1736
[7]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[8]   Prediabetes, Prehypertension ... Is It Time for Pre-CKD? [J].
Curhan, Gary C. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (04) :557-559
[9]   Treatment of Metabolic Syndrome Slows Progression of Diabetic Nephropathy [J].
Duran-Perez, Edgar G. ;
Almeda-Valdes, Paloma ;
Cuevas-Ramos, Daniel ;
Campos-Barrera, Eugenia ;
Munoz-Hernandez, Liliana ;
Gomez-Perez, Francisco J. .
METABOLIC SYNDROME AND RELATED DISORDERS, 2011, 9 (06) :483-489
[10]   Effect of a multifactorial intervention on mortality in type 2 diabetes [J].
Gaede, Peter ;
Lund-Andersen, Henrik ;
Parving, Hans-Henrik ;
Pedersen, Oluf .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (06) :580-591